Drug Profile
Research programme: anti-EphA4 monoclonal antibodies - AstraZeneca
Alternative Names: Anti-EphA4 mAb - AstraZeneca; MEDI-542Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 05 Feb 2008 Preclinical development is ongoing
- 19 Jun 2007 MedImmune has been acquired by AstraZeneca
- 16 Jun 2006 This programme is still in active development